Title:
FUSION GENE OF KIF5B GENE AND RET GENE, AND METHOD FOR DETERMINING EFFECTIVENESS OF CANCER TREATMENT TARGETING FUSION GENE
Document Type and Number:
WIPO Patent Application WO/2013/018882
Kind Code:
A1
Abstract:
The present invention relates to a novel method for identifying a gene which may be an indicator for predicting the effectiveness of medicine-based cancer treatment and predicting the effectiveness of the treatment targeting the gene. As a result of carrying out overall transcriptome sequencing for pulmonary adenocarcinoma, an in-frame fusion transcription product of a KIF5B gene and an RET gene was identified. KIF5B-RET gene fusion was detected in 6/319 cases (2%) of pulmonary adenocarcinoma in Japanese subjects and in 1/80 cases (1%) of pulmonary adenocarcinoma in American subjects, and it was found that the gene fusion was a causative mutation (driver mutation) in the development of cancer as none of the seven cases showed a well-known activated mutation, i.e. EGFR, KRAS, and ALK oncogenes. The gene fusion is thought to cause constant activation of the RET tyrosine kinase protein, and it was discovered that a treatment using an RET tyrosine kinase protein inhibitor was effective for patients in which the gene fusion has been detected.
Inventors:
KOHNO TAKASHI (JP)
TSUTA KOJI (JP)
TSUTA KOJI (JP)
Application Number:
PCT/JP2012/069799
Publication Date:
February 07, 2013
Filing Date:
August 03, 2012
Export Citation:
Assignee:
NAT CANCER CT (JP)
KOHNO TAKASHI (JP)
TSUTA KOJI (JP)
KOHNO TAKASHI (JP)
TSUTA KOJI (JP)
International Classes:
C07K14/82; A61K45/00; A61P35/00; C07K16/32; C12N15/09
Domestic Patent References:
| WO2010000012A1 | 2010-01-07 | |||
| WO2007049624A1 | 2007-05-03 | |||
| WO2012053606A1 | 2012-04-26 |
Foreign References:
| JP2010509289A | 2010-03-25 |
Other References:
HERBST, R. S. ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 359, 2008, pages 1367 - 1380
PAEZ, J. G. ET AL., SCIENCE, vol. 304, 2004, pages 1497 - 1500
TAKEUCHI, K. ET AL., CLIN CANCER RES, vol. 15, 2009, pages 3143 - 3149
SODA, M. ET AL., NATURE, vol. 448, 2007, pages 561 - 566
JANKU, F. ET AL., NAT REV CLIN ONCOL, vol. 7, 2010, pages 401 - 414
LOVLY, C. M. ET AL., NAT REV CLIN ONCOL, vol. 8, 2011, pages 68 - 70
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268
PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
KRAMER, W.; FRITZ, H J., METHODS ENZYMOL, vol. 154, 1987, pages 350
TOTOKI Y ET AL., NAT GENET., vol. 43, no. 5, May 2011 (2011-05-01), pages 464 - 469
TAKANO, T. ET AL., J CLIN ONCOL., vol. 23, 2005, pages 6829 - 6837
NANNYA, Y. ET AL., CANCER RES., vol. 65, 2005, pages 6071 - 6079
IWAKAWA, R. ET AL.: "MYC Amplification as a Prognostic Marker of Early Stage Lung Adenocarcinoma Identified by Whole Genome Copy Number Analysis", CLIN CANCER RES., 10 December 2010 (2010-12-10)
MEYERSON, M. ET AL., NAT REV GENET, vol. 11, 2010, pages 685 - 696
MANI, R. S. ET AL., NAT REV GENET, vol. 11, 2010, pages 819 - 829
WELLS, S. A., JR. ET AL., CLIN CANCER RES, vol. 15, 2009, pages 7119 - 7123
HIROKAWA, N., NAT REV MOL CELL BIOL, vol. 10, 2009, pages 682 - 696
BLANCO, R. ET AL., HUM MUTAT, vol. 30, 2009, pages 1199 - 1206
SHIGEMATSU, H. ET AL., JNATL CANCER INST, vol. 97, 2005, pages 339 - 346
See also references of EP 2740742A4
PAEZ, J. G. ET AL., SCIENCE, vol. 304, 2004, pages 1497 - 1500
TAKEUCHI, K. ET AL., CLIN CANCER RES, vol. 15, 2009, pages 3143 - 3149
SODA, M. ET AL., NATURE, vol. 448, 2007, pages 561 - 566
JANKU, F. ET AL., NAT REV CLIN ONCOL, vol. 7, 2010, pages 401 - 414
LOVLY, C. M. ET AL., NAT REV CLIN ONCOL, vol. 8, 2011, pages 68 - 70
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268
PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
KRAMER, W.; FRITZ, H J., METHODS ENZYMOL, vol. 154, 1987, pages 350
TOTOKI Y ET AL., NAT GENET., vol. 43, no. 5, May 2011 (2011-05-01), pages 464 - 469
TAKANO, T. ET AL., J CLIN ONCOL., vol. 23, 2005, pages 6829 - 6837
NANNYA, Y. ET AL., CANCER RES., vol. 65, 2005, pages 6071 - 6079
IWAKAWA, R. ET AL.: "MYC Amplification as a Prognostic Marker of Early Stage Lung Adenocarcinoma Identified by Whole Genome Copy Number Analysis", CLIN CANCER RES., 10 December 2010 (2010-12-10)
MEYERSON, M. ET AL., NAT REV GENET, vol. 11, 2010, pages 685 - 696
MANI, R. S. ET AL., NAT REV GENET, vol. 11, 2010, pages 819 - 829
WELLS, S. A., JR. ET AL., CLIN CANCER RES, vol. 15, 2009, pages 7119 - 7123
HIROKAWA, N., NAT REV MOL CELL BIOL, vol. 10, 2009, pages 682 - 696
BLANCO, R. ET AL., HUM MUTAT, vol. 30, 2009, pages 1199 - 1206
SHIGEMATSU, H. ET AL., JNATL CANCER INST, vol. 97, 2005, pages 339 - 346
See also references of EP 2740742A4
Attorney, Agent or Firm:
CENTCREST IP ATTORNEYS (JP)
Patent business corporation cent Crest international patent firm (JP)
Patent business corporation cent Crest international patent firm (JP)
Download PDF:
Claims:
Previous Patent: DISPOSABLE ARTICLE FOR WEARING
Next Patent: CANCER TREATMENT AND/OR PREVENTION DRUG COMPOSITION
Next Patent: CANCER TREATMENT AND/OR PREVENTION DRUG COMPOSITION